Qing Shang2, Xiang Wang2, David W. Dumbauld1, Milind Singh1, Mike Apley3, Butch Kukanich4, and Cory Berkland1,2
1Orbis Biosciences, Inc., Kansas City, KS, 66103, USA; 2Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS, 66045, USA; 3Department of Clinical Sciences, Kansas State University, Manhattan, KS, 66506, USA; 4Department of Anatomy and Physiology, Kansas State University, Manhattan, KS, 66506
Most analgesics require multiple oral administrations per day which frequently leads to poor compliance and often results in insufficient control over pharmacokinetic profiles. While sustained release injectable formulations offer improved compliance, they typically result in drug ‘burst’, followed by imprecise pharmacokinetics resulting in lack of tight control over the concentration of these drugs in the blood. Here, we explore the possibility of developing a safer, more effective extended pain reliever using Orbis Bioscience’s controlled release technology to reformulate a generic NSAID into a long-lasting injectable depot.